The 2026 Vaccine Schedule: Cost, Coverage, and Employer Playbook.
The 2026 CDC vaccine schedule for children and adults — updated COVID-19 and flu formulations, RSV guidance, Shingrix and HPV schedules, and the employer preventive-care playbook that funds the entire schedule at zero member cost-share.
The 2026 CDC vaccine schedule carries its most significant updates in years. The COVID-19 vaccine has moved from emergency authorization into the routine annual calendar alongside flu. The seasonal flu shot returned to a trivalent formula after four years as a quadrivalent, because the B/Yamagata lineage has not been detected globally since 2020. RSV vaccination expanded from a narrow elderly window to include pregnant women at 32 to 36 weeks gestation. What has not changed is the confusion around which shots you actually need, how much they cost, and whether your employer plan covers them. This guide resolves all three.
TL;DR
- The 2025-2026 COVID-19 vaccine targets the JN.1 lineage. Recommended for everyone 6 months and older, prioritized for adults 65+ and immunocompromised patients.
- The 2025-2026 flu vaccine returns to a trivalent formula (two influenza A strains plus one influenza B/Victoria strain).
- Shingrix (50+), HPV series (9 to 26), RSV (60+ and pregnancy 32-36 weeks), pneumococcal (65+), and Tdap every 10 years cover the highest-impact adult shots.
- ACA-compliant employer plans cover all ACIP-recommended vaccines at $0 cost-share in-network.
- A Section 125 cafeteria plan recaptures the FICA on every pre-tax health-benefit dollar, which fully funds preventive care at zero employer net cost.
What changed for 2026
The 2026 CDC schedules reflect three real shifts. First, the annual COVID-19 vaccine has moved into the routine adult and pediatric schedule. Second, the seasonal flu vaccine transitioned from quadrivalent to trivalent because the B/Yamagata lineage has not been detected in global surveillance since March 2020. Third, RSV vaccination expanded from a narrow 60+ window to a broader 60+ recommendation with a maternal dose at 32 to 36 weeks gestation to protect newborns.
The pediatric schedule also added the maternal RSV dose to the prenatal column and clarified the use of nirsevimab (a monoclonal antibody, not a vaccine) for infants whose mothers did not receive the maternal RSV dose.
The 2026 childhood vaccine schedule
The pediatric schedule covers birth through age 18. The core series remains stable. Below is a simplified view of what most U.S. children receive on time.
| Age | Vaccines | Notes |
|---|---|---|
| Birth | Hep B (1st dose) | Within 24 hours |
| 2 months | DTaP, Hib, IPV, PCV, RV, Hep B | Combination shots common |
| 4 months | DTaP, Hib, IPV, PCV, RV | |
| 6 months | DTaP, Hib, PCV, RV, Hep B, COVID, Flu | Annual flu starts |
| 12-15 months | MMR, varicella, Hep A, Hib, PCV | First MMR + chickenpox |
| 4-6 years | DTaP, IPV, MMR, varicella | School-entry boosters |
| 11-12 years | Tdap, HPV, MenACWY | HPV: 2-dose if <15 |
| 16 years | MenACWY booster, MenB |
The complete and authoritative schedule lives at the CDC pediatric schedule page. Pediatricians use the catch-up schedule for children who missed early doses.
The 2026 adult vaccine schedule
Adult vaccination is more complex because eligibility is keyed to age, condition, and risk factor rather than a fixed calendar. Below is the high-impact 2026 baseline.
High-impact adult vaccines to prioritize
| Age | Recommended vaccine | Schedule |
|---|---|---|
| 19+ | Annual flu, COVID-19 booster | Annual / per ACIP |
| 19+ | Tdap → Td or Tdap booster | Once Tdap, then every 10 years |
| 19-26 | HPV | 2-3 doses, gender-neutral |
| 19-59 | Hep B (3 doses) | If unvaccinated |
| 50+ | Shingrix (RZV) | 2 doses, 2-6 months apart |
| 60+ | RSV (Arexvy or Abrysvo) | Single dose, shared decision |
| 65+ | Pneumococcal (PCV20 or PCV15+PPSV23) | Per ACIP |
| Pregnancy | Tdap (27-36 wk), RSV (32-36 wk), Flu, COVID |
Adults with diabetes, asthma, immunocompromise, or chronic kidney disease have additional vaccine recommendations, particularly hep B and pneumococcal. The complete schedule lives at the CDC adult schedule page.
COVID vaccine 2025-2026 update
The 2025-2026 COVID-19 vaccine is a single-strain monovalent formulation targeting the JN.1 lineage and its descendants. FDA approved or authorized three options.
- Pfizer-BioNTech (Comirnaty) — mRNA, ages 6 months and up.
- Moderna (Spikevax) — mRNA, ages 6 months and up.
- Novavax — protein subunit, ages 12 and up. Useful for patients who prefer a non-mRNA option.
CDC recommends a single 2025-2026 dose for everyone 6 months and older, with a second dose at least two months later for adults 65+ and moderately or severely immunocompromised patients. Side-effect profile and contraindications match prior seasons; myocarditis risk remains highest in young males with the second mRNA dose, and the absolute incidence is small.
Flu vaccine 2025-2026 strain composition
The 2025-2026 northern-hemisphere flu vaccine is trivalent and targets:
- An A/H1N1 strain
- An A/H3N2 strain
- A B/Victoria-lineage strain
The shift from quadrivalent to trivalent reflects the continued absence of B/Yamagata-lineage influenza in global surveillance since March 2020. Adults 65+ should receive one of the high-dose or adjuvanted formulations: Fluzone High-Dose Quadrivalent, Fluad Quadrivalent, or Flublok Quadrivalent. Egg-allergy precautions have been removed for all formulations except live-attenuated FluMist.
RSV: who actually needs it
The 2026 RSV recommendation is one of the schedule's most underused. Three populations qualify.
- Adults 60 and older — single-dose Arexvy or Abrysvo, shared clinical decision-making with the patient's clinician.
- Pregnant women at 32 to 36 weeks gestation during September through January — Abrysvo, to provide passive antibody protection to the newborn.
- Infants — nirsevimab monoclonal antibody (not a vaccine) if the mother did not receive the maternal RSV dose.
RSV hospitalization is a leading cause of admission in infants under six months and in adults over 75. The 2026 recommendation closed a meaningful gap.
Shingles, HPV, hep B and other adult shots
Shingrix is the single highest-impact adult vaccine after flu and COVID. Two doses two to six months apart deliver greater than 90% efficacy against shingles for at least a decade. Recommended for everyone 50 and older, including those who previously received Zostavax.
HPV vaccination is recommended through age 26 for everyone, with shared clinical decision-making to age 45. The 2-dose schedule applies if the first dose is given before age 15; otherwise a 3-dose series. HPV prevents most cervical, anal, and oropharyngeal cancers caused by HPV.
Hepatitis B is now recommended for all adults 19 to 59. The 2026 schedule simplified prior risk-based eligibility. Pneumococcal vaccination at 65+ uses either the single-dose PCV20 or the PCV15 + PPSV23 sequence.
What vaccines cost in 2026
In-network ACA-compliant insurance covers ACIP-recommended vaccines at $0. The cash list price still matters for the uninsured and for travel vaccines.
| Vaccine | Cash list price (typical) | ACA-plan cost-share |
|---|---|---|
| Flu (standard) | $25–$55 | $0 in-network |
| COVID-19 (2025-2026) | $130–$200 | $0 in-network |
| Shingrix (per dose, 2 doses) | $200 | $0 in-network |
| HPV (per dose, 2-3 doses) | $260 | $0 in-network |
| RSV (Arexvy / Abrysvo) | $295 | $0 in-network |
| Tdap (booster) | $70 | $0 in-network |
| MMR | $95 | $0 in-network |
| Hepatitis B (per dose, 3 doses) | $80 | $0 in-network |
| PCV20 (pneumococcal) | $310 | $0 in-network (65+) |
| Yellow fever (travel) | $220 | Usually not covered |
How employers cover vaccines without raising premiums
The ACA already requires the coverage. The opportunity for employers is two-fold: make existing coverage visible, and fund the small remaining out-of-pocket through a Healthcare FSA inside a Section 125 cafeteria plan.
- Communications — quarterly benefits comms that surface preventive-care coverage measurably lift adult vaccination rates.
- Healthcare FSA — eligible for vaccine copays, travel vaccines, and any out-of-pocket from an out-of-network pharmacy. Read the 2026 FSA limits article for the contribution mechanics.
- Section 125 — the entire framework that makes pre-tax health benefits work. The complete §125 employer guide walks through how the FICA recapture funds preventive-care programs at zero net employer cost.
- Pharmacy benefit — in-network pharmacy partners (CVS, Walgreens, Walmart, Costco) administer most ACIP vaccines without an appointment.
Frequently asked questions
- What is the 2026 CDC vaccine schedule?
- The CDC publishes two annual schedules: one for children and adolescents (birth through age 18) and one for adults age 19+. The 2026 schedules retain the core series — DTaP, Hib, IPV, MMR, varicella, hepatitis B, PCV, rotavirus, HPV, meningococcal — and add the 2025-2026 COVID-19 vaccine and the seasonal flu vaccine. Adults age 50+ are recommended Shingrix, and adults age 65+ are recommended Pneumovax 23 or PCV20.
- Is there a new COVID vaccine in 2025-2026?
- Yes. FDA-approved 2025-2026 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax target the JN.1 lineage and its descendants. CDC recommends the updated dose for everyone 6 months and older, with priority for adults 65+ and immunocompromised patients.
- Is the flu vaccine different in 2025-2026?
- Yes. The 2025-2026 seasonal flu vaccine is a trivalent formulation (one fewer strain than recent quadrivalent versions) because the B/Yamagata lineage has not been detected in global surveillance since 2020. It targets two influenza A strains and one influenza B/Victoria strain. The high-dose Fluzone HD and adjuvanted Fluad remain recommended for adults 65+.
- How much do vaccines cost without insurance in 2026?
- Cash list prices vary widely. The flu shot runs $25 to $55, the COVID-19 shot $130 to $200, Shingrix is approximately $200 per dose for two doses, the HPV series is around $260 per dose for three doses, and the RSV vaccine (Arexvy or Abrysvo) is approximately $295 per dose. Most ACA-compliant insurance covers ACIP-recommended vaccines at $0 cost-share when received in-network.
- Are vaccines mandatory for children in 2026?
- School-entry vaccine requirements are set by each U.S. state, not the federal government. Every state requires a core set (typically MMR, DTaP, polio, varicella, hepatitis B) for public school enrollment, with medical and (in most states) religious or personal-belief exemptions. The 2026 Florida vaccine-mandate debate did not change federal recommendations.
- Is there an mRNA cancer vaccine?
- Multiple mRNA cancer vaccines are in clinical trials in 2026, including melanoma and pancreatic cancer programs from Moderna and BioNTech. None are FDA-approved for routine use yet. The currently approved cancer-prevention vaccines are HPV (cervical, anal, oropharyngeal cancers) and hepatitis B (liver cancer).
- Do employer health plans cover all CDC-recommended vaccines?
- Yes, when the plan is ACA-compliant. Section 2713 of the ACA requires non-grandfathered group plans to cover all ACIP-recommended vaccines at $0 in-network cost-share. The flu, COVID-19, Shingrix, HPV, RSV, hepatitis B, MMR, and the full pediatric schedule are all included.
- Can a Section 125 plan be used to pay for vaccines?
- Yes. Vaccines that qualify as IRC §213(d) medical expenses are eligible for a Healthcare FSA inside a Section 125 cafeteria plan, including any out-of-pocket vaccine cost not covered by the underlying medical plan. Travel vaccines (yellow fever, typhoid) prescribed by a physician are also eligible.
Continue reading
- GLP-1 Medications 2026: Costs, Coverage & the Employer Playbook — Pharmacy & Rx
Ozempic, Wegovy, Mounjaro, Zepbound. What employers should know about the most-searched drug class.
- Employee Health Benefits 2026: The Definitive Guide — Employee Benefits
How preventive care, vaccines, and pharmacy fit into the modern 2026 employer benefit stack.
- FSA Contribution Limits 2026 and the Use-It-or-Lose-It Rule — Employee Benefits
How a Healthcare FSA inside a §125 plan covers vaccine copays and over-the-counter meds.
About the author
Muhammad Mudassir — Co-founder & Health Tech Sales Lead
Muhammad Mudassir, who goes by Moe, is a co-founder and health technology operator focused on Section 125 cafeteria plans and zero-cost employer benefits. He has spent years getting employers enrolled in compliant cafeteria plans, onboarding nationwide workforces into the WoW Health and UnifyWell ecosystems, and translating the mechanics of FICA recapture into language that HR, finance, and ownership can act on.